Trial of Cinpanemab in Early Parkinson’s Disease

2022314 citationsJournal Articlebronze Open Access

Authors

Anthony E. Lang · University of Toronto

Andrew Siderowf · University of Pennsylvania

Eric A. Macklin · Massachusetts General Hospital

Werner Poewe · Innsbruck Medical University

David J. Brooks · Newcastle University

Hubert H. Fernandez · Inserm

Olivier Rascol ·

Abstract

In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period. (Funded by Biogen; SPARK ClinicalTrials.gov number, NCT03318523.).

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Alzheimer's disease research and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 5, pp. 408-420

DOI: 10.1056/nejmoa2203395

Field-Weighted Citation Impact: 37.46